Immunome Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
The following documents are filed as part of this Annual Report on Form 10-K
| (1) | Financial Statements |
Our consolidated financial statements listed in the “Index to the Consolidated Financial Statements” and Report of Independent Registered Public Accounting Firm are included after this Part IV, Item 15, “Exhibits and Financial Statement Schedules” of this Annual Report on Form 10-K.
(2) Financial Statement Schedules
None.
(3) Exhibits
The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated therein.
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| | |
|---|---|
| | Page |
| | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42) | 119 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 120 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | 121 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022 | 122 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | 123 |
| Notes to the Consolidated Financial Statements | 124 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.